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 Introduction 
 Psoriasis vulgaris (PSO) and atopic dermatitis (AD) 
are among the most important dermatological condi-
tions in terms of prevalence, health-related quality of life 
(HRQL) impact, and societal economic burden  [1–10] . 
While most cases of AD and PSO can be effectively con-
trolled with emollients and topical treatments, some pa-
tients with extensive disease, outpatient treatment fail-
ure, acute deterioration, or highly impaired everyday 
functioning require inpatient care. Recently, administra-
tive and financial pressures have led to a reduction both 
in bed numbers and average duration of inpatient treat-
ment  [11] . These structural changes in the health servic-
es in Europe also led to modifications of the aims of hos-
pitalizing patients with chronic relapsing skin diseases. 
While previously complete clearance was the goal, we 
now try to improve the symptoms sufficiently to allow 
outpatient treatment. In patients with severe AD or PSO, 
this might be problematic, as the chances of relapsing ear-
ly after discharge might be high if inpatient management 
solely focuses on present symptoms.
 HRQL is the main outcome from the patient’s perspec-
tive  [7, 12–14] . Highly impaired HRQL is associated with 
decreased treatment satisfaction and adherence  [15–18] . 
HRQL is significantly more impaired in hospitalized pa-
tients than in outpatients  [19] . A stable benefit in HRQL 
after discharge might therefore be the key determinant to 
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 Abstract 
 Background: Financial constraints challenge evidence of 
the effectiveness of dermatological inpatient management. 
 Objective: To evaluate the effectiveness of hospitalization in 
atopic dermatitis and psoriasis regarding initial and sus-
tained benefits.  Methods: Prospective study on adults with 
psoriasis vulgaris (n = 22) and atopic dermatitis (n = 14). At 
admission, discharge, and 3 months after discharge, validat-
ed outcomes of objective and subjective disease severity 
were assessed by trained investigators.  Results: Hospitaliza-
tion resulted in substantial benefit in quality of life and clin-
ical disease severity. Looking at mean scores, the observed 
benefit appeared stable until 3-month follow-up. The analy-
sis of individual patient data revealed significant changes in 
disease severity between discharge and 3-month follow-up 
with some patients relapsing, others further improving. Rea-
sons for hospitalization and treatment performed were not 
related to sustained benefit.  Conclusions: In psoriasis vul-
garis and atopic dermatitis, hospitalization effectively im-
proved quality of life and clinical disease severity. Further 
research should focus on prognostic factors for sustained 
improvement.   Copyright © 2007 S. Karger AG, Basel 
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avoid readmission by increasing the compliance to and 
therefore the effectiveness of outpatient care.
 Recently, it has been shown that hospitalization im-
proves HRQL in patients with PSO and AD  [11, 19] . How-
ever, as these studies followed their patients only until 1 
week and 1 month after discharge, respectively, the long-
term effect of hospitalization on HRQL in patients with 
PSO and AD remains unknown.
 We conducted a prospective study on adult patients 
with PSO and AD. At admission, discharge, and 3 months 
after discharge, HRQL, clinical disease severity, and self-
assessed global disease severity were assessed. Our re-
search questions included whether hospitalization is ben-
eficial for objective and subjective disease severity, and 
whether disease severity remains stable between dis-
charge and 3-month follow-up visit.
 Methods 
 Setting and Study Population 
 This prospective monocenter study was carried out between 
July 2003 and May 2004 at the Department of Dermatology, Uni-
versity Hospital Dresden, Germany. The study followed the prin-
ciples  outlined in the Declaration of Helsinki  [20] .
 Eligibility criteria included age of 18 years or older, hospital-
ization because of PSO or AD, i.e. one of these conditions had to 
be the referral diagnosis, chronic course of the disease over at least 
6 months, and first hospitalization because of one of the studied 
conditions within the study period.
 Out of 62 patients eligible for participation, informed consent 
was obtained from 36 (58%; PSO: n = 22; AD: n = 14). Seven eli-
gible patients were not recruited because of admission when none 
of the investigators was on call, e.g. during the weekend. Nine 
eligible patients were unwilling to participate because of logistical 
difficulties, e.g. long geographical distance to the study site. Rea-
sons for nonparticipation remained unclear in 10 eligible patients. 
Follow-up rate was 81% (total: n = 29; PSO: n = 16; AD: n = 13). 
From the 7 patients lost to follow-up, 1 PSO patient died (cause 
unrelated to PSO); the other 6 patients refused to participate in 
the follow-up visit after 2 written reminders.
 Data Collection 
 The study consisted of 3 study visits, which were performed by 
2 specifically trained investigators (E.H., J.S.). The baseline visit 
(first study visit) and second study visit were performed within
24 h after admission and 24 h before discharge, respectively. The 
follow-up visit was scheduled at 12  8 2 weeks after discharge. 
Sociodemographic characteristics and information on specific 
personal and family disease history were collected at baseline. 
Additionally, the reason for hospitalization and the treatment 
performed during hospitalization were recorded at admission 
and at discharge, respectively. HRQL, physician-assessed objec-
tive disease severity, and patient-assessed global disease severity 
were recorded at each study visit in order to measure the most 
important aspects of the dermatologic morbidity.
 The Dermatology Life Quality Index (DLQI) was introduced 
by Finlay and Khan  [12] in 1994 to measure HRQL in dermato-
logical patients  [21] . It consists of 10 questions considering the 
domains symptoms and feelings, daily activities, leisure, work 
and school, personal relationships, and treatment during the pre-
vious week. The DLQI score ranges from 0 to 30 with higher 
scores reflecting worse HRQL. The DLQI has adequate psycho-
metric properties. It has frequently been applied in studies on AD 
and PSO  [12, 21–23] .
 Objective clinical disease severity was assessed by means of 
the Psoriasis Area and Severity Index (PASI) in PSO, and the Ec-
zema Area and Severity Index (EASI) in AD  [24, 25] . Both mea-
surements have frequently been applied in clinical trials to define 
eligibility or to measure efficacy  [25–28] . Both intensity and ex-
tent of the specific skin lesions are scored separately for 4 ana-
tomical regions (head, trunk, upper and lower extremities) by the 
physician using Likert scales. When calculating the PASI and 
EASI, the 4 anatomical regions are valued according to their pro-
portion of the whole integument. The PASI and EASI score both 
range from 0 to 72 with higher scores indicating higher objective 
severity  [24, 25] .
 Patients were asked to rate their global disease severity on a 
10-cm Visual Analogue Scale (VAS) with ‘0’ indicating complete 
remission, and ‘10’ indicating highest imaginable severity.
 Data Analysis 
 Baseline characteristics of patients with PSO and AD were 
summarized by means and standard deviations. The    2  test/Fish-
er exact test (binary and ordinal variables), and the t test (con-
tinuous variables) were used to compare baseline characteristics 
by condition; t tests were applied to test whether mean differ-
ences in severity scores between study visits were equal to zero.
 Our alternative hypothesis was that the mean DLQI score dif-
fers clinically significantly between the baseline and 3-month fol-
low-up visit. According to published data, a difference in the DLQI 
of 5 points was considered clinically relevant from the patient’s 
perspective  [22] . With a type I error probability of 0.05, a 2-sided 
statistical test, and an assumed standard deviation of the DLQI 
difference, the study power was 99.9% if all patients with complete 
follow-up (n = 29) were considered as a single population. When 
considering patients with AD (n = 13) and PSO (n = 16) separate-
ly, the study power was 91.1 and 95.9%, respectively  [29] .
 The question whether the mean change in the severity score 
differs by follow-up status was analyzed using the Wilcoxon 
matched-pairs signed-rank test. The normality assumption was 
tested using skewness/kurtosis and Shapiro-Wilk tests  [30] .
 Additionally to mean scores, we also looked at individual pa-
tient data and calculated the proportions of patients experiencing 
clinically relevant changes in disease severity between different 
study visits. For this purpose, a relevant improvement was de-
fined as a relative decrease in severity score by 20% or more, and 
a relevant worsening as a relative increase in severity by 20% or 
more. The question whether relevant worsening between dis-
charge and 3-month follow-up visit was related to sociodemo-
graphic characteristics, reason for admission, and/or treatment 
performed during hospitalization was analyzed using logistic re-
gression models. The association of outcomes and length of inpa-
tient treatment was tested by Spearman rank correlation  [30] . All 
statistical analyses were performed using Stata statistical software 
8.0 for Windows  [31] .
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 Results 
 Sociodemographic and clinical characteristics of the 
study population at baseline are summarized in  table 1 . 
Except for age, there were no statistically significant dif-
ferences in socioeconomic characteristics by condition. 
A positive family history was observed in high propor-
tions of patients with PSO (45.0%) and AD (42.9%). Dis-
ease severity at admission was high in terms of HRQL 
impairment, clinical severity, and self-assessed global 
disease severity. The mean DLQI score of all patients at 
baseline was 16.2  8 7.6. AD was associated with a non-
significantly higher impact on HRQL compared to PSO 
(AD: 18.2  8 9.1; psoriasis: 15.1  8 6.9). Differences in 
other severity measurements were not statistically sig-
nificant either, so that all patients could be analyzed as 
one group for consecutive analyses ( table 1 ). The average 
duration of hospitalization was 11.3  8 5.2 days in pa-
tients with PSO compared to 9.4  8 3.3 days in AD pa-
tients (p = 0.24).
 The most common reasons necessitating admission 
were acute deterioration of disease (42.2%), outpatient 
treatment failure (38.9%), and initiation of systemic treat-
ment (13.9%). Twenty patients (55.6%) received systemic 
anti-inflammatory treatment (including UV therapy); 
the remaining 16 patients (44.4%) were treated exclusive-
Table 1. Baseline characteristics by diagnosis (n = 36)
Variable All patients
(n = 36)
PSO patients
(n = 22)
AD patients
(n = 14)
p value for difference
by diagnosisb
Females, % 47.2 50.0 42.9 0.68
Age (mean 8 SD), years 46.1818.0 54.6815.2 32.8814.2 <0.01
Disease duration (mean 8 SD), years 30.3818.5 31.6820.2 28.3816.0 0.61
Married, % 47.2 50.5 35.7 0.27
Less than 10 years of education, % 19.4 22.7 14.3 0.53
Unemployed, % 19.4 22.7 14.3 0.53
Income less than 1,000 EUR/month, % 77.1 76.2 78.6 0.87
Positive family history, % 44.1 45.0 42.9a 0.90
DLQI (mean 8 SD) 16.287.6 15.186.9 18.289.1 0.26
EASI/PASI (mean 8 SD) 23.9815.6 21.3814.6 28.1816.7 0.20
Disease severity, VAS (mean 8 SD) 6.782.2 6.882.5 6.681.7 0.75
a For atopy (AD, pollinosis, allergic asthma).
b For difference between patients with AD and PSO, unpaired t test or 2 test was performed, as appropriate.
Table 2. Mean differences in objective and subjective disease severity scores between admission and discharge/3-month follow-up 
visit, and mean differences in severity scores between discharge and 3-month follow-up visit 
Variable Change from admission to 
discharge (n = 36)
Change from admission to 
3-month follow-up (n = 29)
Change from discharge to 
3-month follow-up (n = 29)
mean (SEM) p value for
difference = 0
mean (SEM) p value for
difference = 0
mean (SEM) p value for
difference = 0
DLQI 7.7 (1.1) <0.001 9.1 (1.5) <0.001 0.9 (1.5) 0.55
EASI/PASI 13.8 (1.9) <0.001 12.5 (2.2) <0.001 –0.9 (2.3) 0.68
Disease severity (VAS) 2.9 (0.5) <0.001 2.7 (0.5) <0.001 –0.6 (0.6) 0.40
Effectiveness of hospitalization is expressed as mean differences in objective and subjective disease severity scores between admis-
sion and discharge/3-month follow-up visit (first columns). Stability of benefit is expressed as mean differences in severity scores be-
tween discharge and 3-month follow-up visit (last column). 
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 Fig. 1.  a Mean DLQI at admission, dis-
charge, and 3-month follow-up by diagno-
sis.  b Mean EASI or mean PASI at admis-
sion, discharge, and 3-month follow-up
by diagnosis.  c Mean self-assessed global 
disease severity (VAS) at admission, dis-
charge, and 3-month follow-up by diagno-
sis. 
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ly with topical agents. Reasons for admission and treat-
ment during hospitalization did not differ significantly 
by diagnosis.
 Analysis of Mean Changes in Outcome Measures 
 During hospitalization, the mean DLQI dropped by 
7.7 (95% CI 5.5–9.9). Parallel to the decrease in HRQL 
impairment, we observed a substantial benefit in terms 
of both clinical severity, and patient-rated global disease 
severity (PASI/EASI change 13.8, 95% CI 10.0–17.6; VAS 
change 2.9, 95% CI 1.9–3.9;  table 2 ). The magnitude of 
improvement was comparable between patients with AD 
and PSO ( fig. 1 ).
 The positive effect of hospitalization on clinical symp-
toms and HRQL appeared to be stable. This can be con-
cluded for two reasons: firstly, the decrease in all severity 
measurements between admission and 3-month follow-
up was highly statistically significant (p  ! 0.001 for each 
score); secondly, there was no statistical difference in any 
mean outcome measure between discharge and 3-month 
follow-up visit ( table 2 ).
 The duration of hospitalization was neither associated 
with the benefit in DLQI between admission and dis-
charge (p = 0.36), nor with the change in DLQI between 
admission and 3-month follow-up visit (p = 0.71). There 
was no statistically significant association either between 
improvement in HRQL and age (p = 0.22) or income (p = 
0.28). The mean change in DLQI between admission and 
discharge was similar in men and women (p = 56; men: 
6.95 points; women: 8.24 points).
 As shown in  figure 1 , the mean changes in outcomes 
were similar in patients with PSO and AD. Significant 
and stable benefit was observed in all dimensions of the 
DLQI ( fig. 2 ).
 Differences in benefit from inpatient treatment were 
similar in patients who completed the follow-up visit and 
those who did not (decrease in DLQI 7.8 vs. 6.8; p = 0.80; 
decrease in EASI/PASI 13.7 vs. 14.6; p = 0.55; decrease in 
VAS 3.1 vs. 2.0; p = 0.51). This indicates that selection bias 
due to dropouts is not present.
 Analysis of Individual Patient Data 
 High proportions of patients achieved a relevant im-
provement in HRQL (77.8%), clinical (97.2%), and global 
disease severity (63.8%) ( table 3 ).
 In similarly high proportions of patients, we observed 
a clinically relevant decrease in disease severity at 3-
month follow-up compared to admission (DLQI: 79.3%; 
EASI/PASI: 86.2%; VAS: 75.8%). Only few patients expe-
rienced worsening of disease severity during hospitaliza-
tion (DLQI: 5.6%; EASI/PASI: 0.0%; VAS: 2.8%) or be-
tween admission and 3-month follow-up visit (DLQI: 
6.9%; EASI/PASI: 0.0%; VAS: 6.9%) ( table 3 ).
 Although the mean change between discharge and 3-
month follow-up visit was not statistically significant for 
any outcome, high proportions of patients further im-
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 Fig. 2. Mean DLQI scores for HRQL do-
mains at admission, discharge, and 3-
month follow-up visit. 
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proved (DLQI: 55.7%; EASI/PASI: 44.8%; VAS: 41.6%), 
whereas a comparably high proportion experienced rel-
evant worsening of the skin disease (DLQI: 41.4%; EASI/
PASI: 34.5%; VAS: 45.8%) ( table 3 ).
 Figure 3 graphically displays the absolute scores in 
DLQI ( fig. 3 a) and PASI/EASI ( fig. 3 b) for every patient 
separately. Although there is an overall downward trend 
both in HRQL and clinical severity, the individual re-
sponse curves show that some patients clearly relapsed 
until 3 months after discharge. Relevant worsenings of 
DLQI, PASI or EASI, or global disease severity (VAS) 
were not associated with any of the ascertained sociode-
mographic characteristics. The likelihood of relapse was 
not associated with the diagnosis either (DLQI: p = 0.34; 
PASI/EASI: p = 0.93).
 The duration of hospitalization was neither associated 
with change in disease severity between admission and 
discharge, nor with relapse after discharge. Worsening 
after discharge was neither related with the reason for 
hospital admission (DLQI: p = 0.58; PASI/EASI: p = 0.76), 
nor with the treatment performed during hospitalization 
(DLQI: p = 0.35; PASI/EASI: p = 0.29).
 Discussion 
 Hospitalization of patients with PSO and AD led to a 
significant benefit in all relevant dimensions of HRQL. 
Evidence of effectiveness of inpatient treatment on DLQI 
was also shown in studies from the USA and UK  [11, 19] . 
The extent of DLQI improvement observed in these stud-
ies was similar to our sample. Generalizability may be 
assumed, as the findings from the different settings are 
consistent. Parallel to the HRQL improvement, we ob-
served significant reductions in clinical disease severity 
and self-assessed global disease severity. Our conclusion 
that hospitalization is effective is strong, as it is consistent 
in both analyses, i.e. when looking at mean changes in 
scores and at proportions of individual patients achieving 
relevant improvements.
 The presented study extends previous research on the 
effectiveness of hospitalization as it focuses on the 3-
month period after discharge. Previous studies had only 
followed their patients up to 1 month after discharge. 
Looking at mean scores or at proportions of patients 
showing relevant relative improvement at 3 months after 
discharge compared to hospital admission suggests that 
patients remain in remission. However, looking more pre-
cisely at the response curves of individual patients reveals 
that there is much change both in HRQL impairment and 
clinical symptoms within 3 months after discharge. Nei-
ther length of hospitalization nor sociodemographic 
characteristics, nor the treatment performed during hos-
pitalization, nor the reason for hospitalization predicted 
relevant worsening after discharge. Other factors that 
might explain early relapse include patient’s satisfaction 
with treatment, compliance after discharge, and the de-
gree to which the patient himself was allowed to make an 
informed choice of the available therapeutic options. Un-
fortunately, none of these factors was assessed in this or 
Table 3. Proportion of patients with relevant change in objective and subjective disease severity scores between admission and dis-
charge/3-month follow-up visit, and proportion of patients with relevant change in severity scores between discharge and 3-month 
follow-up visit 
Variable Proportion of patients with 
relevant change between ad-
mission and discharge, %
(n = 36) 
Proportion of patients with 
relevant change between ad-
mission and 3-month follow-
up, % (n = 29)
Proportion of patients with 
relevant change between dis-
charge and 3-month follow-
up, % (n = 29)
better equal worse better equal worse better equal worse
DLQI 77.8 16.6 5.6 79.3 13.8 6.9 51.7 6.9 41.4
EASI/PASI 97.2 2.8 0.0 86.2 13.8 0.0 44.8 20.7 34.5
Disease severity (VAS) 63.8 33.4 2.8 75.8 17.2 6.9 41.6 12.6 45.8
Effectiveness of hospitalization is expressed as the proportion of patients with relevant change (defined as 20% relative improve-
ment to prior assessment) in objective and subjective disease severity scores between admission and discharge/3-month follow-up 
visit (first columns). Stability of benefit is expressed as the proportion of patients with relevant change in severity scores between dis-
charge and 3-month follow-up visit (last column). 
 Schmitt/Heese/Wozel/Meurer
 
Dermatology 2007;214:68–7674
other studies, so that it remains unclear why some pa-
tients experienced a relapse early after discharge.
 Clearly, there is an overall benefit of hospitalization, 
which appears to be both substantial and stable for at least 
3 months after discharge when analyzing mean scores. 
All other studies on the effectiveness of hospitalization 
chose changes in mean scores as outcome  [11, 19, 32] . Our 
study clearly shows that the inference regarding the sta-
bility of remission drawn from the whole study popula-
tion, e.g. changes in mean scores, is contrary to the con-
clusion drawn from the patients’ individual response 
curves. When applying the results from this study to ev-
eryday clinical practice this difference is critically impor-
tant. The conclusion for the individual patient is that hos-
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 Fig. 3.  a DLQI in individual patients at ad-
mission, discharge, and 3-month follow-
up.  b EASI or PASI in individual patients 
at admission, discharge, and 3-month fol-
low-up. 
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pitalization is likely to substantially improve a patient’s 
HRQL as well as the extent and intensity of the skin le-
sions, but that stable remission is only achieved in a sub-
group of patients.
 Despite the relatively small sample size, our study was 
sufficiently powerful to answer our primary research 
question whether hospitalization leads to a mean im-
provement in HRQL which is meaningful for the pa-
tient.
 A possible drawback, however, is that a high propor-
tion of eligible patients could not be recruited. Therefore, 
the presented data should be interpreted with caution in 
terms of generalizability. It cannot be excluded that fac-
tors affecting the willingness to participate in our study 
are related to HRQL. However, in most of these cases
(n = 15, 60%), the reasons for nonparticipation were lo-
gistical or organizational, so that we do not think that 
generalizability is a major concern.
 Differences in benefit from hospitalization were simi-
lar in patients who completed the follow-up visit and 
those who did not, indicating that selection bias due to 
dropouts is unlikely. 
 Another possible limitation of our study is that no 
control group was used. The relative importance of der-
matological inpatient management should be investigat-
ed by comparing inpatient and outpatient treatment pro-
tocols.
 Further research is necessary to evaluate prognostic 
factors for sustained improvement. Inpatient treatment 
protocols that consider such factors are likely to improve 
the cost-effectiveness of hospitalization. Higher effec-
tiveness of inpatient treatment with sustained benefit af-
ter discharge might be achieved by intensively informing 
and educating the patient during hospitalization. Such 
interventions might induce a sustained behavior change, 
better compliance to outpatient treatment options, and 
overall higher efficiency of dermatological care in gen-
eral.
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